COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
15/09/2025
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular [...]
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
15/09/2025
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity [...]
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
15/09/2025
Dr. Pandya brings 20 years of drug development expertise in precision medicine in both oncology and hematology, with previous senior leadership roles at Servier Pharmaceuticals and Agios Pharmaceuticals Her appointment [...]

Pages